Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity

Clinical Lung Cancer

Volumn 14, Issue 5, 2013, Pages 502-507

  Takimoto, Takayuki ^a   Kijima, Takashi ^b   Otani, Yasushi ^b   Nonen, Shinpei ^c,d   Namba, Yoshinobu ^e   Mori, Masahide ^e   Yokota, Soichiro ^e   Minami, Seigo ^f   Komuta, Kiyoshi ^f   Uchida, Junji ^g   Imamura, Fumio ^g   Furukawa, Mitsugi ^h   Tsuruta, Naotoshi ⁱ   Fujio, Yasushi ^c   Azuma, Junichi ^d   Tachibana, Isao ^b   Kumanogoh, Atsushi ^b  

^a TOYONAKA MUNICIPAL HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

^e TONEYAMA NATIONAL HOSPITAL   (Japan)

^f OSAKA POLICE HOSPITAL   (Japan)

^g OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^h Saiseikai Senri Hospital   (Japan)

ⁱ Nishinomiya Municipal Central Hospital   (Japan)

Author keywords

CYP2D6; Erlotinib; Gefitinib; Hepatotoxicity; Polymorphisms

Indexed keywords

AMINOTRANSFERASE; AMLODIPINE; CARVEDILOL; CEVIMELINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DILTIAZEM; ERLOTINIB; GEFITINIB; NIFEDIPINE;

ADULT; AGED; ALLELE; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RECHALLENGE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; JAPANESE; LIVER TOXICITY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; RETREATMENT; SIDE EFFECT;

CYP2D6; ERLOTINIB; GEFITINIB; HEPATOTOXICITY; POLYMORPHISMS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2D6; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER DISEASES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 84883794602     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.03.003     Document Type: Article

References (33)

1. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
2. T. Mitsudomi, S. Morita, and Y. Yatabe Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
3. M. Maemondo, A. Inoue, and K. Kobayashi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
4. R. Rosell, T. Moran, and C. Queralt Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 2009 958 967
5. C. Zhou, Y.L. Wu, and G. Chen Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
6. M. Fukuoka, S. Yano, and G. Giaccone Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [corrected] J Clin Oncol 21 2003 2237 2246
7. N. Seki, K. Uematsu, and R. Shibakuki Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration J Clin Oncol 24 2006 3213 3214 author reply 3214-5
8. M. Takeda, I. Okamoto, and M. Fukuoka Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity J Clin Oncol 28 2010 e273 e274
9. W.M. Lee Drug-induced hepatotoxicity N Engl J Med 349 2003 474 485
10. R.J. Andrade, J.A. Agúndez, and M.I. Lucena Pharmacogenomics in drug induced liver injury Curr Drug Metab 10 2009 956 970
11. F. Sun, Y. Chen, and Y. Xiang Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis Int J Tuberc Lung Dis 12 2008 994 1002
12. R. Kumashiro, T. Kubota, and Y. Koga Association of troglitazone-induced liver injury with mutation of the cytochrome P450 2C19 gene Hepatol Res 26 2003 337 342
13. J. Li, M. Zhao, and P. He Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes Clin Cancer Res 13 2007 3731 3737
14. D. McKillop, A.D. McCormick, and A. Millar Cytochrome P450-dependent metabolism of gefitinib Xenobiotica 35 2005 39 50
15. H.C. Swaisland, M.V. Cantarini, and R. Fuhr Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics Clin Pharmacokinet 45 2006 633 644
16. H.C. Swaisland, M. Ranson, and R.P. Smith Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol Clin Pharmacokinet 44 2005 1067 1081
17. Y. Gasche, Y. Daali, and M. Fathi Codeine intoxication associated with ultrarapid CYP2D6 metabolism N Engl J Med 351 2004 2827 2831
18. Y. Jin, Z. Desta, and V. Stearns CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 2005 30 39
19. C.F. Samer, Y. Daali, and M. Wagner Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety Br J Pharmacol 160 2010 919 930
20. M.Y. Morgan, R. Reshef, and R.R. Shah Impaired oxidation of debrisoquine in patients with perhexiline liver injury Gut 25 1984 1057 1064
21. M. Kitada Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6 Int J Clin Pharmacol Res 23 2003 31 35
22. K. Kim, J.A. Johnson, and H. Derendorf Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms J Clin Pharmacol 44 2004 1083 1105
23. L.D. Bradford CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants Pharmacogenomics 3 2002 229 243
24. Y. Nishida, T. Fukuda, and I. Yamamoto CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10 Pharmacogenetics 10 2000 567 570
25. T. Kijima, T. Shimizu, and S. Nonen Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism J Clin Oncol 29 2011 e588 e590
26. Y. Ikenaga, T. Fukuda, and K. Fukuda The frequency of candidate alleles for CYP2D6 genotyping in the Japanese population with an additional respect to the -1584C to G substitution Drug Metab Pharmacokinet 20 2005 113 116
27. I. Johansson, E. Lundqvist, and M.L. Dahl PCR-based genotyping for duplicated and deleted CYP2D6 genes Pharmacogenetics 6 1996 351 355
28. V.M. Steen, O.A. Andreassen, and A.K. Daly Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology Pharmacogenetics 5 1995 215 223
29. X. Li, T.M. Kamenecka, and M.D. Cameron Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities Chem Res Toxicol 22 2009 1736 1742
30. S. Chhun, C. Verstuyft, and N. Rizzo-Padoin Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers Br J Clin Pharmacol 68 2009 226 237
31. S.F. Zhou, C.C. Xue, and X.Q. Yu Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring Ther Drug Monit 29 2007 687 710
32. J. Li, M.O. Karlsson, and J. Brahmer CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors J Natl Cancer Inst 98 2006 1714 1723
33. A.R. Tan, X. Yang, and S.M. Hewitt Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor J Clin Oncol 22 2004 3080 3090